4,651 guests

The other drug war

They say that imitation is the best compliment.

Fake clothes, shoes, bags, watches, and other fashion accessories.

All these we can marginally tolerate.

After all not all people can afford the real thing, especially the designer or premium brands.

But when it comes to food and drugs, there should be zero tolerance for fake products.
This is simply because public health and safety is at stake here.
Therefore, the government should always be on the lookout for imitation food and medical products.
But the focus should be on counterfeit medicines because they pose serious threat to the health and well-being of people.
And this is a basic constitutional duty of the government.
It is right there in the general welfare clause of the fundamental law of the land.
Any government that is remiss in this duty has no right to be in power one minute longer.
Thankfully, state regulators and law enforcers are on their toes hunting down illicit traders or importers who distribute fake food and medicines in the country.
This is much appreciated as the nation enters the holiday season during which imports of food and medicines traditionally rise. 
And so we are glad to know that aside from drug pushers, police officers would also be running after manufacturers and distributors of counterfeit drugs and unregistered food products.
The Food and Drug Administration signed an agreement on Tuesday with the National Police to step up the campaign against fake drugs available in the market.
Under the agreement, the PNP would get an annual budget of P25 million as part of the government’s efforts to stop the proliferation of fake and substandard drugs, which pose health risks to the public.
FDA director general Nela Charade Puno said the agency would fund the PNP’s operations with an initial amount of P15 million.
Puno said the PNP would investigate and conduct search and seizure operations as well as arrest individuals involved in the production and distribution of unregistered medicine and food products.
“The lack of FDA manpower should not be an excuse for substandard drugs to proliferate,” she said.